India
based Venus Remedies gets market authorisation for oncology drugs from Swiss
authority
Pharma major Venus
Remedies has secured its first marketing authorisation in Switzerland from
Swiss drug authority 'Swissmedic' for its oncology drug 'Gemcitabine'. The
marketing approval for Gemcitabine will help the company further strengthen its
oncology portfolio and improve its presence in this space, Venus Remedies said
in a statement here today.
The Panchkula-based
company plans to launch the drug early next quarter and the product will be
launched in Switzerland by Swiss Pharma GmbH, with which Venus has a marketing
tie-up, it said.
"The launch of this
product will add to the company's top line and bottom line in the coming
quarters," it said.
Venus Remedies has already
received more than 20 marketing approvals for Gemcitabine injection from
various countries. The product is being sold in the UK, Poland and Germany.
Gemcitabine is an
anti-cancer drug used for the treatment of a variety of cancerous conditions,
including the cancer of the lungs, pancreas, bladder and breast.
No comments:
Post a Comment